NOT-DA-21-082: Notice of Intent to Publish a Funding Opportunity Announcement for Accelerating the Pace of Drug Abuse Research Using Existing Data (R21 Clinical Trial Optional)

Notice of Intent to Publish a Funding Opportunity Announcement for Accelerating the Pace of Drug Abuse Research Using Existing Data (R21 Clinical Trial Optional)

Notice Number:

NOT-DA-21-082

Key Dates

Release Date:

September 14, 2021

Estimated Publication Date of Funding Opportunity Announcement:

January 08, 2022

First Estimated Application Due Date:

February 05, 2022

Earliest Estimated Award Date:

May 01, 2022

Earliest Estimated Start Date:

September 01, 2022

Related Announcements

PAR-19-163 - Accelerating the Pace of Child Health Research Using Existing Data from the Adolescent Brain Cognitive Development (ABCD) Study (R21-Clinical Trial Not Allowed)

NOT-DA-21-070- Notice to Extend the Expiration Date for PAR-19-163, "Accelerating the Pace of Child Health Research Using Existing Data from the Adolescent Brain Cognitive Development (ABCD) Study (R21-Clinical Trial Not Allowed)

Issued by

National Institute on Drug Abuse (NIDA)

Purpose

The National Institute on Drug Abuse (NIDA) intends to reissue PAR-19-163 "Accelerating the Pace of Child Health Research Using Existing Data from the Adolescent Brain Cognitive Development (ABCD) Study (R21-Clinical Trial Not Allowed)" to seek applications proposing innovative analysis of existing social science, behavioral, administrative, and neuroimaging data to study the etiology and epidemiology of substance-using behaviors (defined as alcohol, tobacco, prescription, and other substances) and related disorders, prevention of substance use and HIV, and health service utilization.

This Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects.

The Funding Opportunity Announcement (FOA) is expected to be published in January 2022 with an expected application due date in February 2022.

This FOA will utilize the R21 activity code.

Details of the planned FOA are provided below.

Research Initiative Details

This FOA encourages the analyses of public use and other extant community-based or clinical datasets to their full potential in order to increase our knowledge of etiology, trajectories of substance-using behaviors and associated consequences including morbidity and mortality, risk and resilience in the development of psychopathology, strategies to guide the development, testing, implementation, and delivery of high quality, effective and efficient services for the prevention and treatment of substance use disorder and HIV. Primary data collection is not allowed for applications in response to this FOA.

Funding Information

Estimated Total Funding

NIDA intends to commit $2 million in FY 2022.

Expected Number of Awards

4-6 awards

Estimated Award Ceiling

TBD

Primary Assistance Listing Number(s)

TBD

Anticipated Eligible Organizations

Private Institution of Higher Education
Indian/Native American Tribal Government (Other than Federally Recognized)
U.S. Territory or Possession
Eligible Agencies of the Federal Government
Regional Organization
Non-domestic (non-U.S.) Entity (Foreign Organization)
Indian/Native American Tribally Designated Organization (Native American tribal organizations (other than Federally recognized tribal governments)
Public housing authorities/Indian housing authorities
Independent school districts
County governments
Indian/Native American Tribal Government (Federally Recognized)
State Government
Nonprofit with 501(c)(3) IRS Status (Other than Institution of Higher Education)
For-Profit Organization (Other than Small Business)
Small Business
Public/State Controlled Institution of Higher Education

Applications are not being solicited at this time.

Inquiries

Please direct all inquiries to:

Marsha F. Lopez, Ph.D., M.H.S

National Institute on Drug Abuse (NIDA)

240-535-6066

[email protected]

Elizabeth Hoffman, Ph.D. (for ABCD applications)
National Institute on Drug Abuse (NIDA)
Telephone: 301.594.2265
Email: [email protected]